



AE-PCOS

ANDROGEN EXCESS & PCOS SOCIETY

18TH ANNUAL MEETING
NOVEMBER 7-8, 2020
VIRTUAL MEETING

CALL FOR ABSTRACTS

Submission Deadline

11:00 PM (23h00) PST – SEPTEMBER 18th, 2020

You are invited to submit abstracts of your original research to be considered for presentation at the 18th Annual Meeting of the Androgen Excess & Polycystic Ovary Syndrome Society (AE-PCOS Society). To be considered for presentation, your abstract must be submitted no later than **SEPTEMBER 18th, 2020 at 11:00 pm (23h00) PST**.

All abstracts will be reviewed and scored by a blinded scientific committee nominated by AEPCOS Annual Meeting Committee.

INSTRUCTIONS FOR SUBMISSION OF ABSTRACTS

Please read the following guidelines thoroughly before preparing your abstract. The Annual Meeting Scientific Committee of the AE-PCOS will not consider abstracts that have not been prepared in accordance with these instructions.

All abstracts must be submitted by email. Please note the presenter is required to register for 17th Annual Meeting of the AE-PCOS Society (see www.ae-society.org).

Submission of an abstract assumes the approval of the author and all co-author(s) to have their abstract published in the Annual Meeting Program book. Copyright of accepted abstracts will automatically be assigned to the AE-PCOS Society, Inc.

SUBMITTING YOUR ABSTRACT

1. The abstract should be as informative as possible (see [Sample Abstract](#) below).
2. If accepted, your abstract will appear in the Meeting Program book published exactly as submitted and any typing errors will be visible.
3. The AE-PCOS Society reserves the right to decide on the form of presentation (oral or poster) in the interests of the Scientific Program.
4. It is understood that the first author of the abstract will serve as the presenter, and that the presenter will be registered for 18th Annual Meeting of the AE-PCOS Society.
5. Abstracts should be emailed to info@ae-society.org, by **11:00 pm (23h00) PST, September 18th, 2020**.

SAMPLE ABSTRACT

LOW PREVALENCE OF THE V281L MUTATION OF CYP21 AMONG WOMEN WITH THE POLYCYSTIC OVARY SYNDROME (PCOS). Smith JG¹, Jones EB², Bartley MRD². (1) Dept. of Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA and (2) Dept. of Ob/Gyn, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Familial aggregation indicates that genetic factors are important in the pathogenesis of PCOS. In searching for PCOS genes, we and others have reported an increased frequency of heterozygosity for CYP21 mutations, especially the V281L missense mutation, among children with premature pubarche (PP), adolescent girls with hyperandrogenism, and a small cohort of women with PCOS. To determine whether the frequency of the V281L mutation of CYP21 is actually increased in PCOS, and whether this increase is associated with adrenal androgen (AA) excess, we determined the presence of this mutation in 170 women with PCOS and excessive AA secretion, 152 women with PCOS and normal AA secretion, and 94 healthy adult female controls from the Southeastern U.S. Genotyping was performed by PCR followed by allele specific RFLP analysis. PCOS was defined by the presence of oligo-ovulation in combination with clinical evidence of hyperandrogenism (e.g. hirsutism) and/or hyperandrogenemia (e.g. supranormal free testosterone levels), after the exclusion of related disorders, including 21-hydroxylase deficient non-classic adrenal hyperplasia. Our results indicate that in the population studied two women with PCOS, one with AA excess and one without, were heterozygous carriers of V281L. None of the control women carried this CYP21 mutant allele. We can conclude that the V281L mutation of CYP21 is relatively rare among the population of PCOS women studied, regardless of presenting AA levels. Although we cannot exclude the possibility that other CYP21 mutant alleles may be more common in this population, differences in ethnic background may explain the low frequency of heterozygosity for the V281L mutation in this population of PCOS women compared to previous reports. Furthermore, heterozygosity for CYP21 mutations may play a greater role in PP rather than in PCOS (supported in part by NIH grants 2-R01-HD30000 to JGS and R21-HD30000 to MRDB).

Special instructions:

- 1) Use font Times Roman 11.
- 2) Use single space.
- 3) The title should be in caps and bolded.
- 4) Authors should be listed as follows: Last name first, followed by name initials. Affiliation key should follow each name in superscript [e.g. Smith JG¹, Jones EB²].
- 5) Affiliations should note department/division, institution, city, state or province, and country. Each affiliation should be preceded by key in superscript [e.g. (1) Department. of Medicine, Johns Hopkins Hospital, Baltimore, MD, USA].
- 6) A space should be placed between the affiliations and the body of the abstract.
- 7) Please limit your abstract to the space provided.
- 8) Funding sources should be acknowledged at the end of the abstract, in parentheses.
- 9) The form type used will not accept symbols, superscripts, or subscripts so please do not use these. (e.g. do not use "β", instead type "Beta").



ANDROGEN EXCESS & PCOS SOCIETY
18TH ANNUAL MEETING



ABSTRACT SUBMISSION FORM

DEADLINE FOR SUBMISSION: 11:00 PM (23H00) PST, SEPTEMBER 18TH, 2020

Abstracts should be emailed to info@ae-society.org

Title:

Authors:

Affiliations:

Abstract:

Please complete all required fields and submit by email to info@ae-society.org.

By submitting this form, I agree that I have read and understand the AE-PCOS Society abstract submission guidelines for 18th Annual Meeting of AE-PCOS Society, November 7-8, 2020, VIRTUAL MEETING, and if accepted, I will present the abstract in the required form (oral communication or poster). I also certify that all authors listed have approved the submission of the abstract and its publication in the Meeting Program and proceedings, and understand that copyright of the accepted abstracts will automatically be assigned to the AE-PCOS Society.

I am a member of the AE-PCOS Society.

I am a young researcher (<35 years of age)

Presenter Name

Date

Please complete contact information and attach to your electronic submission. You will be assigned an abstract number and notified using the information you list below. Please ensure that all information is correct.

Name (Last, First): _____	
Specialty _____	
Institution _____	

Mailing Address:	
Street Address _____	

City/State	Country
Email: _____	

IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT THE AEPCOS SOCIETY BY EMAIL
info@ae-society.org